Arsenal Biosciences, Inc.
Clinical trials sponsored by Arsenal Biosciences, Inc., explained in plain language.
-
Can engineered immune cells outsmart Drug-Resistant ovarian cancer?
Cure OngoingThis phase 1 trial tests an experimental therapy called AB-1015 in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. AB-1015 uses a patient's own T cells, which are genetically engineered to recognize and…
Phase 1 • Sponsor: Arsenal Biosciences, Inc. • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Engineered t cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a new treatment called AB-3028, which uses a patient's own immune cells (T cells) that have been modified in a lab to better attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to ho…
Phase 1/2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Engineered immune cells take on advanced kidney cancer in new trial
Disease control OngoingThis early-phase trial tests a new treatment called AB-2100 for people with advanced or metastatic clear-cell renal cell carcinoma that has come back after standard treatments. AB-2100 is made from the patient's own immune cells, which are modified in the lab to better recognize …
Phase 1/2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC